HR
EPZM

Howe & Rusling’s Epizyme, Inc EPZM Stock Holding History

Howe & Rusling’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25
Closed – – 1151
2016
Q2 		$0 Hold
25
– – ﹤0.01% 1072
2016
Q1 		$0 Hold
25
– – ﹤0.01% 1074
2015
Q4 		$0 Hold
25
– – ﹤0.01% 1096
2015
Q3 		$0 Hold
25
– – ﹤0.01% 1090
2015
Q2 		$1K Buy
+25
New +$481 ﹤0.01% 1000

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Howe & Rusling's EPZM Position: Q3 2016 in Review

Howe & Rusling sold out of Epizyme, Inc (EPZM) in Q3 2016, closing a stake of 25 shares.

Howe & Rusling first reported a position in EPZM in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q2 2015. 97 funds tracked by Wall St. Rank hold EPZM as of Q3 2016.

  • Howe & Rusling reported no remaining Epizyme, Inc position as of Q3 2016 after selling out during the quarter.
  • Howe & Rusling sold 25 Epizyme, Inc shares in Q3 2016.
  • Howe & Rusling first reported a position in Epizyme, Inc in Q2 2015 and held it in 5 quarters.
  • Howe & Rusling's Epizyme, Inc position peaked at $1K in Q2 2015.
  • 97 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.